News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Biagio Ricciuti: TROPICS-03 trial – Sacituzumab Govitecan in 2L extensive stage SCLC
Jan 6, 2025, 11:35

Biagio Ricciuti: TROPICS-03 trial – Sacituzumab Govitecan in 2L extensive stage SCLC

Biagio Ricciuti, Thoracic oncologist at the Dana-Farber Cancer Institute, shared a post on X:

“TROPICS-03 trial: Sacituzumab Govitecan in 2L extensive stage SCLC.

Ph II (N=43)

ORR 41.9%
– 35% platinum-resistant & 48% in platinum-sensitive)

PFS 4.4 and OS 13.6 months

Promising activity with however high rate of G3+ TRAEs (74.4%).”

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.

Biagio Ricciuti cancer Lung cancer OncoDaily Oncology SCLC
Special Coverage
Career
Mar 31, 2025, 18:22
Maryam Yazdy has been appointed as the Senior Medical Director of Clinical Development at BeiGene
Blog
Mar 31, 2025, 18:21
Cecilia Pompili: PROs research from ELCC25 on NSCLC treatment and thoracic surgery
Blog
Mar 31, 2025, 18:15
Beau Bosko Toskich: Clinical and Dosimetric Guidelines for Y-90 Glass Microsphere Radioembolization
Blog
Mar 31, 2025, 18:09
Ray Chan: Can’t wait for William Dale’s lecture this Thursday at Flinders University
Science
Mar 31, 2025, 18:00
Partha Basu: Guidance from IARC/WHO on validating HPV detection tests with lower valency
Blog
Mar 31, 2025, 17:58
Trends in Outpatient Opioid Prescriptions for Cancer Pain Between 2016 and 2021
Blog
Mar 31, 2025, 17:50
Lauren Averett Byers: Awesome clinic with Dr. Elyse Rose Lopez
Blog
Mar 31, 2025, 17:45
Lianne Mandelbaum: Flying with food allergies - Combating misconceptions and advocating for safety
Blog
Mar 31, 2025, 17:01
Navigating care: understanding cancer patients’ experiences with systemic radionuclide therapy - MASCC
Blog
Mar 31, 2025, 16:46
Join Dr. Nicola Normanno at ISMRC 2025 for insights on biomarker discovery and ctDNA testing
Career
Mar 31, 2025, 16:23
Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy
Blog
Mar 31, 2025, 15:57
Register Today for the 2025 Breast Cancer Symposium